Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi AppTec Completes Hong Kong IPO; Finishes First Trading Session Unchanged

publication date: Dec 13, 2018

WuXi AppTec began trading on the Hong Kong Exchange following its $967 million IPO, finishing the first day of trading at the offer price. In May, the company completed a $354 million Shanghai IPO at a price that has now quadrupled after six months. From the start, WuXi planned to have a dual Shanghai-Hong Kong listing, following the low-priced Shanghai IPO with a higher priced Hong Kong offering. If the underwriters exercise their over-allotment option, the value of IPO will climb to over $1.1 billion. More details....

Stock Symbol: (SHA: 603259; HK: 2359)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here